Orphazyme A/S is a biopharmaceutical company, which engages in the research and development of treatments for rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
1
Frequently Asked Questions
What is Market Cap of Orphazyme A/S - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Orphazyme A/S - ADR market cap is $1.06M.
What is the 52-week high for Orphazyme A/S - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Orphazyme A/S - ADR 52 week high is $7.48 as of September 19, 2025.
What is the 52-week low for Orphazyme A/S - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Orphazyme A/S - ADR 52 week low is $0.0002 as of September 19, 2025.
What is Orphazyme A/S - ADR stock price today?
Orphazyme A/S - ADR stock price today is $0.03.
What was Orphazyme A/S - ADR stock price yesterday?
Orphazyme A/S - ADR stock price yesterday was $0.08.
What is the PE ratio of Orphazyme A/S - ADR?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Orphazyme A/S - ADR’s P/E ratio is -0.01.
What is the Price-to-Book ratio of Orphazyme A/S - ADR?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Orphazyme A/S - ADR P/B ratio is 0.7344.
What is Orphazyme A/S - ADR's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Orphazyme A/S - ADR's EBITDA is N/A.
What is the 50-day moving average of Orphazyme A/S - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Orphazyme A/S - ADR 50-day moving average is $0.2066.